Clinical Trial: Efficacy and Safety of Donafenib Plus Iparomlimab and Tuvonralimab Combined with Capecitabine in Postoperative Adjuvant Treatment for Biliary Tract Malignancies (China)

Posted On: 2026-09-02

China, Sept. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Donafenib Plus Iparomlimab and Tuvonralimab Combined with Capecitabine in Postoperative Adjuvant Treatment for Biliary Tract Malignancies'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131377

Registration Time: 2026/09/01

Type: Interventional study

Primary Sponsor: Affiliated Hospital of North Sichuan Medical College

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337156

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy and Safety of Donafenib Plus Iparomlimab and Tuvonralimab Combined with Capecitabine in Postoperative Adjuvant Treatment for Biliary Tract Malignancies (China)